Stock Analysis
Novartis AG (NVS) Stock Analysis
Novartis AG (NVS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Novartis AG (NVS) currently has an AIQ Score of 61/100, indicating a neutral setup. Risk is the strongest factor at 76/100. Value is the weakest current factor at 49/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NVS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $160.50 |
| AIQ Score | 61/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $304.31B |
| P/E Ratio (TTM) | 30.72 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.63 |
| Revenue (Q3 FY2026) | $15.03B |
| Dividend Yield (TTM) | 2.76% |
| Beta | 0.37 |
| Volume | 1.42M |
| 52-week range | $123.24-$170.46 |
| RSI 14 | 58.46 |
| 50-Day SMA | $149.13 |
| 200-Day SMA | $152.57 |
| Analyst Price Target | $149.50 |
| Next Earnings | Feb 3, 2027 |
NVSNovartis AG
Healthcare / Drug Manufacturers - General
Low Priority
Above Peers
Latest quote
- Momentum64
- Value49
- Quality58
- Risk resilience76
- Sentiment—
NVS Stock Analysis Summary
Novartis AG (NVS) currently has an AIQ Score of 61/100, indicating a neutral setup. Risk resilience is the strongest factor at 76/100. Value is the weakest current factor at 49/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, NVS has AIQ Score of 61/100 with Risk resilience base of 76/100 and fading Value at 49/100. Wait for component alignment before adding exposure.
Risk resilience (76/100) leads while Value (49/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.16% stock move · NVS classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NVS Bullish or Bearish Right Now?
NVS currently has a neutral overall setup. Risk Resilience is the strongest factor at 76/100, while Value is weakest at 49/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Risk Resilience is supportive at 76/100.
- - Price is +7.62% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (27 vs 8).
- - Value is the current constraint at 49/100.
- - Analyst target implies -6.85% downside from the latest quote.
Current Consensus
NVS's Technical Analysis Consensus is currently Buy, with 27 buy, 11 neutral, and 8 sell votes. NVS's 14-day RSI is 58.46, which places the stock in a constructive momentum range. NVS's beta is 0.37, indicating lower market sensitivity than the broad market.
What Changed in NVS?
The largest recent change in NVS is Momentum moving down by 2.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the NVS Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NVS Decision Framework
Public evidence layers, setup checks, and risk context for Novartis AG.
Novartis AG (NVS) Stock Analysis
Novartis AG has an AIQ Score of 61/100 in a Neutral regime. Risk is strongest at 76/100. Beta is 0.37, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NVS is in a Neutral AIQ regime with score 61/100. |
| Signal Conflict | The primary conflict is that risk leads at 76/100 while value lags at 49/100. |
| Factor Evidence | Momentum 64/100 · Value 49/100 · Quality 58/100 · Risk 76/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 76/100.
Momentum is 64/100 and RSI (14) is 58.5.
NVS is in a Neutral regime at 61/100.
Risk factor is 76/100 with beta 0.37 and annual volatility 27.23%.
Current conflict: risk leads at 76/100 while value lags at 49/100.
NVS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NVS Fundamentals
NVS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NVS Technical Analysis
NVS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NVS Stock Catalysts
Track NVS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NVS Dividend Analysis
NVS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NVS Financial Data
NVS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NVS Risk Analysis
NVS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NVS Stock News
NVS stock news, market tone, recent headlines, and catalyst context.
NVS vs Drug Manufacturers - General Peers
Current peer cohort: NVS · SNY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NVS Current stock | 61/100 | 49/100 | 64/100 | 76/100 | 0.72 | 27.23% | Current |
| SNY Sanofi | 68/100 | 77/100 | 64/100 | 85/100 | -0.37 | 24.14% | NVS vs SNY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for NVS: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NVS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NVS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NVS Stock FAQ
What is NVS stock price today?
Novartis AG's current stock price is $160.50. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NVS bullish or bearish right now?
NVS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NVS's market cap?
NVS's market cap is $304.31B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NVS's current P/E ratio?
NVS's current P/E ratio is 30.72 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NVS's RSI?
NVS's 14-day RSI is 58.46 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NVS above its 50-day and 200-day moving averages?
NVS is 7.62% from its 50-day SMA and 5.20% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NVS's next earnings date?
NVS's next earnings date is currently listed as Feb 3, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NVS pay a dividend?
NVS's dividend yield is 2.76% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.